<sup>68</sup>Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy
Helena Lanzafame(Düsseldorf University Hospital), Wolfgang P. Fendler(Essen University Hospital), Sebastian Bauer(University of Duisburg-Essen), Martin Schüler(Essen University Hospital), Michael A. Nader(Essen University Hospital), Kim M. Pabst(Klinik und Poliklinik für Nuklearmedizin), Mélanie Desaulniers(Université de Sherbrooke), Jens T. Siveke(German Cancer Research Center), Nader Hirmas(Deutsches Konsortium für Translationale Krebsforschung), Rainer Hamacher(Technical University of Munich), Ilektra A. Mavroeidi(German Cancer Research Center), Francesco Barbato(Deutsches Konsortium für Translationale Krebsforschung), Ken Herrmann(Essen University Hospital), Stephan Leyser(Düsseldorf University Hospital), Marc Ingenwerth(Deutschen Konsortium für Translationale Krebsforschung), Timo Bartel(Essen University Hospital), Lukas Kessler(Düsseldorf University Hospital)
Cited by 36
Related Papers
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k